1 Classification and types
Corticosteroids are steroid hormones that share a common core structure but differ in their dominant physiologic roles. In clinical practice, they are grouped according to their effects on carbohydrate metabolism, inflammation, and salt balance. This classification helps explain why some agents are favored for replacement therapy, while others are used mainly for suppressing immune or inflammatory activity.
1.1 Glucocorticoids
Glucocorticoids are the best-known corticosteroids in medicine. They influence glucose metabolism, stress responses, and immune signaling, and they are widely prescribed for anti-inflammatory and immunosuppressive purposes. Common examples include hydrocortisone, prednisone, prednisolone, methylprednisolone, dexamethasone, and betamethasone.
1.2 Mineralocorticoids
Mineralocorticoids mainly regulate sodium retention, potassium excretion, and water balance. Aldosterone is the principal natural mineralocorticoid in humans, though fludrocortisone is commonly used as a synthetic replacement drug. These agents are especially important in conditions involving adrenal insufficiency.
1.3 Natural versus synthetic corticosteroids
Natural corticosteroids are produced by the adrenal cortex, whereas synthetic versions are manufactured to adjust potency, duration, tissue selectivity, and route of administration. Synthetic compounds often provide stronger anti-inflammatory effects or more predictable pharmacokinetics than endogenous hormones. Some are designed for topical or inhaled use to reduce systemic exposure.
1.4 Potency and duration of action
Corticosteroids vary in potency, mineralocorticoid activity, and biological half-life. Short-acting agents such as hydrocortisone resemble the body’s own cortisol more closely, while longer-acting drugs such as dexamethasone produce prolonged effects. Clinicians choose an agent based on the desired intensity of action, the need for adrenal replacement, and the risk of adverse effects.
2 Pharmacology
The pharmacology of corticosteroids centers on their ability to regulate gene activity and alter inflammatory signaling. Their effects are broad because steroid receptors are present in many tissues throughout the body. This wide distribution explains both their therapeutic value and their potential for systemic side effects.
2.1 Mechanism of action
Corticosteroids act primarily by binding intracellular receptors and changing the transcription of target genes. This process leads to reduced production of inflammatory mediators and altered immune cell function. The overall result is decreased swelling, pain, and immune activation in many disease states.
2.1.1 Steroid receptor binding
After entering a cell, corticosteroids bind to glucocorticoid or mineralocorticoid receptors in the cytoplasm or nucleus. The resulting receptor complex moves to the cell nucleus, where it interacts with DNA. This receptor-ligand interaction initiates the downstream pharmacologic response.
2.1.2 Gene transcription effects
The receptor complex influences transcription by increasing or decreasing the expression of specific genes. Some genes involved in anti-inflammatory pathways are upregulated, while others responsible for cytokine production and immune activation are suppressed. These changes occur over hours rather than minutes, which is why many steroid effects are not immediate.
2.1.3 Anti-inflammatory pathways
Corticosteroids reduce the formation of prostaglandins, leukotrienes, and inflammatory cytokines. They also limit migration of white blood cells into inflamed tissue and decrease capillary permeability. These actions contribute to their effectiveness in asthma, autoimmune disease, and allergic reactions.
2.2 Pharmacokinetics
The absorption, distribution, metabolism, and elimination of corticosteroids depend on the specific compound and formulation. Differences in lipid solubility, protein binding, and hepatic metabolism influence onset and duration. These factors are important when selecting a dosage form and adjusting treatment.
2.2.1 Absorption
Corticosteroids may be absorbed through the gastrointestinal tract, skin, lungs, or directly through injection. Oral and inhaled forms are commonly used for chronic disease management, while intravenous preparations are preferred when rapid action is needed. Topical absorption varies with skin thickness, inflammation, and the potency of the product.
2.2.2 Distribution
Once absorbed, corticosteroids circulate in the blood, often bound to plasma proteins such as corticosteroid-binding globulin and albumin. They distribute into multiple tissues, including the liver, muscle, and immune cells. Highly lipophilic agents may penetrate tissues more efficiently and persist longer.
2.2.3 Metabolism
Most corticosteroids are metabolized in the liver through enzymatic pathways that modify their structure and reduce activity. Some prodrugs are converted into active forms after administration, such as prednisone becoming prednisolone. Hepatic function can therefore influence drug levels and treatment response.
2.2.4 Excretion
Metabolites are excreted mainly in the urine after hepatic processing. Smaller amounts may be eliminated through bile and feces. The rate of excretion contributes to differences in half-life among corticosteroid preparations.
2.3 Tissue and receptor specificity
The clinical effect of a corticosteroid depends on receptor affinity, tissue penetration, local enzymatic conversion, and the balance between glucocorticoid and mineralocorticoid activity. Some tissues respond more strongly because of higher receptor density or greater exposure to the drug. This specificity helps explain why certain agents are chosen for skin, lung, joint, or adrenal applications.
3 Medical uses
Corticosteroids are used across many areas of medicine because they can rapidly reduce inflammation, suppress immune activity, and replace deficient adrenal hormones. Their indications range from acute emergencies to long-term maintenance therapy. Careful selection of dose, route, and duration is essential to limit harm.
3.1 Respiratory disorders
In respiratory medicine, corticosteroids are among the most important anti-inflammatory therapies. They are used to reduce airway swelling, improve breathing, and prevent exacerbations. Inhaled preparations are common for chronic disease, while systemic forms are reserved for more severe episodes.
3.1.1 Asthma
Corticosteroids are a mainstay of asthma management because they decrease airway inflammation and bronchial hyperresponsiveness. Inhaled corticosteroids are often used for long-term control, while oral or intravenous agents may be given during severe attacks. Their use lowers symptom frequency and reduces the risk of exacerbations.
3.1.2 Chronic obstructive pulmonary disease
In chronic obstructive pulmonary disease, corticosteroids are used selectively, especially during acute flare-ups. They can shorten recovery time and improve lung function during exacerbations. Long-term inhaled use may benefit some patients, though the choice depends on clinical severity and response.
3.2 Allergic conditions
Corticosteroids are effective in treating allergic disorders because they reduce tissue inflammation and immune reactivity. They may be used for allergic rhinitis, urticaria in selected settings, severe dermatitis, and acute allergic reactions when appropriate. In these cases, they complement other therapies rather than replace emergency treatment when rapid intervention is required.
3.3 Autoimmune and inflammatory diseases
Many autoimmune and inflammatory disorders respond to corticosteroids because these drugs suppress excessive immune activation. They are often used to control flares, induce remission, or bridge treatment until slower-acting medicines take effect. The choice of regimen depends on disease severity and organ involvement.
3.3.1 Rheumatoid arthritis
In rheumatoid arthritis, corticosteroids can reduce joint pain, stiffness, and swelling. They may be used as short-term adjuncts during disease flares or while other disease-modifying therapies are being started. Long-term use is generally limited because of cumulative adverse effects.
3.3.2 Inflammatory bowel disease
Corticosteroids help control inflammatory bowel disease by decreasing intestinal inflammation. They are frequently used to manage acute relapses of Crohn disease or ulcerative colitis. Because they do not maintain remission well and can cause systemic effects, they are usually not preferred for prolonged maintenance therapy.
3.3.3 Systemic lupus erythematosus
Systemic lupus erythematosus often requires corticosteroids to suppress inflammatory activity in the skin, joints, kidneys, or other organs. Doses are tailored to disease severity, and treatment may range from low-dose oral therapy to high-dose pulse administration. The goal is to control flares while minimizing toxicity.
3.4 Dermatologic conditions
Corticosteroids are widely used in skin disease because they reduce redness, itching, and swelling. Topical preparations are commonly prescribed for eczema, psoriasis in selected forms, contact dermatitis, and other inflammatory dermatoses. Potency is chosen according to lesion location, thickness of skin, and severity of the condition.
3.5 Neurologic and ophthalmic uses
In neurology and ophthalmology, corticosteroids are used for conditions involving inflammation or edema. They may be given to reduce cerebral swelling in selected situations or to treat inflammatory eye disorders. Ophthalmic formulations are also used for anterior segment inflammation under medical supervision.
3.6 Endocrine replacement therapy
Corticosteroids serve an essential role in hormone replacement when the body cannot produce adequate adrenal hormones. In this setting, treatment aims to mimic physiologic cortisol or mineralocorticoid production. Replacement therapy differs from anti-inflammatory therapy because the objective is normalization rather than suppression.
3.6.1 Adrenal insufficiency
In adrenal insufficiency, patients require glucocorticoid replacement and sometimes mineralocorticoid replacement. Hydrocortisone and fludrocortisone are common choices, depending on the underlying disorder. Treatment must also be adjusted during illness, surgery, or other physiologic stress.
3.6.2 Congenital adrenal hyperplasia
Congenital adrenal hyperplasia is treated with corticosteroids to replace deficient hormones and suppress excess adrenal androgen production. Therapy helps restore hormonal balance and prevent complications of cortisol deficiency. Management often requires long-term follow-up and dose adjustment over time.
3.7 Transplantation and immunosuppression
Corticosteroids are used in transplantation to reduce the immune response against transplanted organs. They may be part of induction therapy, maintenance regimens, or treatment for acute rejection episodes. Their broad immunosuppressive effect makes them useful, though they are often combined with other agents.
3.8 Oncologic and supportive care uses
In oncology, corticosteroids may be used to reduce inflammation, treat chemotherapy-related nausea, improve appetite, or decrease swelling around tumors. They can also be helpful in certain hematologic malignancies and in palliative care. These uses reflect their versatility rather than direct anticancer activity alone.
4 Routes of administration
Corticosteroids can be delivered through several routes, allowing treatment to be matched to the target organ and desired systemic exposure. The route chosen strongly affects onset, duration, and side-effect profile. Local administration is often preferred when feasible to reduce generalized toxicity.
4.1 Oral corticosteroids
Oral corticosteroids are commonly used for systemic therapy and are convenient for outpatient treatment. They are effective for inflammatory, allergic, and endocrine indications. Because they produce whole-body exposure, dose and duration require careful control.
4.2 Intravenous and intramuscular use
Intravenous corticosteroids are used when rapid action or precise dosing is needed, such as severe asthma, acute allergic reactions, or serious inflammatory disease. Intramuscular formulations may provide prolonged effect or be used when oral therapy is not practical. These routes are often chosen in hospital settings.
4.3 Inhaled corticosteroids
Inhaled corticosteroids deliver medication directly to the airways and are widely used in chronic respiratory disease. They reduce airway inflammation while limiting systemic absorption. Proper inhaler technique is important to maximize benefit and reduce local irritation such as oral candidiasis.
4.4 Topical corticosteroids
Topical corticosteroids are applied to the skin for local inflammatory conditions. Their strength ranges from mild to very potent, depending on the formulation. Factors such as skin thickness, occlusion, and duration of use influence both efficacy and safety.
4.5 Intra-articular and local injections
Intra-articular injections place corticosteroids directly into joints, tendons, or soft tissues to relieve localized inflammation. These injections can provide meaningful symptom relief in selected musculoskeletal disorders. Because repeated use may damage tissue or weaken local structures, they are usually limited.
4.6 Ophthalmic and otic formulations
Eye drops and ear preparations are used for inflammatory conditions affecting the eye or external ear. These formulations aim to concentrate treatment at the site of disease. Medical supervision is important because ocular corticosteroids can raise intraocular pressure or worsen infection.
5 Adverse effects
Corticosteroid adverse effects depend on dose, duration, route, and the particular agent used. Short courses are often well tolerated, but prolonged or high-dose therapy can produce significant complications. The risk-benefit balance therefore requires ongoing assessment.
5.1 Short-term adverse effects
Short-term treatment may cause insomnia, mood changes, increased appetite, indigestion, or transient fluid retention. Some patients notice facial flushing, restlessness, or a temporary rise in blood sugar. These effects are usually reversible when therapy ends or is reduced.
5.2 Long-term adverse effects
Chronic corticosteroid use can affect nearly every organ system. Complications accumulate with prolonged exposure, especially at higher doses. Prevention strategies and monitoring are important when therapy must continue over time.
5.2.1 Osteoporosis
Long-term corticosteroid use can reduce bone formation and increase fracture risk. This is a major concern in adults who require sustained systemic treatment. Calcium, vitamin D, lifestyle measures, and in some cases additional bone-protective therapy may be recommended.
5.2.2 Weight gain and Cushingoid appearance
Prolonged therapy can lead to increased appetite, central weight gain, facial rounding, and fat redistribution. These changes resemble Cushing syndrome and are often distressing to patients. They reflect the metabolic effects of corticosteroids on fat storage and protein balance.
5.2.3 Hyperglycemia and diabetes risk
Corticosteroids may raise blood glucose by increasing insulin resistance and promoting hepatic glucose production. People with diabetes may need closer monitoring or medication adjustment. In some cases, treatment can reveal previously unrecognized impaired glucose regulation.
5.2.4 Hypertension and fluid retention
Some corticosteroids increase sodium retention and contribute to elevated blood pressure or edema. This effect is more pronounced with agents that have mineralocorticoid activity. Patients with cardiovascular risk may require particularly careful monitoring.
5.3 Psychiatric effects
Corticosteroids may cause mood swings, irritability, anxiety, insomnia, or, less commonly, depression, mania, and psychosis. These reactions can occur even with relatively short courses in susceptible individuals. Recognition is important because symptoms may improve after dose reduction or discontinuation.
5.4 Growth suppression in children
Children receiving prolonged corticosteroid therapy may experience slowed growth. This effect is especially relevant when systemic treatment is used repeatedly or continuously. Clinicians often try to use the lowest effective dose and prefer local therapy where appropriate.
5.5 Infection risk and immunosuppression
By suppressing immune responses, corticosteroids can increase vulnerability to bacterial, viral, fungal, and opportunistic infections. They may also mask fever and other signs of illness. The degree of risk depends on dose, duration, and concurrent immunosuppressive drugs.
5.6 Adrenal suppression
Exogenous corticosteroids can suppress the hypothalamic-pituitary-adrenal axis, reducing the body’s own cortisol production. Abrupt withdrawal after prolonged use may lead to adrenal insufficiency. Tapering schedules are often used to allow gradual recovery.
6 Contraindications and precautions
The use of corticosteroids requires attention to preexisting conditions that may worsen under treatment. Some situations are absolute or relative contraindications, while others call for dose modification and careful surveillance. The overall decision depends on the urgency of treatment and the availability of alternatives.
6.1 Active infections
Active infections are an important caution because corticosteroids may suppress immune defenses and delay healing. In some cases, steroids can still be used if benefits outweigh risks, but concurrent treatment of the infection is essential. Clinicians must consider the possibility of hidden or worsening infection.
6.2 Diabetes mellitus
Because corticosteroids can raise blood glucose, diabetes mellitus requires close monitoring. Glucose-lowering treatment may need adjustment during steroid therapy. Patients may also require education about temporary changes in diet, medication, or self-monitoring.
6.3 Peptic ulcer disease
Corticosteroids may aggravate gastrointestinal symptoms and, when combined with other risk factors, contribute to ulcer complications. The risk is higher with concurrent nonsteroidal anti-inflammatory drug use. Protective measures may be considered in selected patients.
6.4 Glaucoma and cataracts
Ocular complications are relevant because corticosteroids can raise intraocular pressure and contribute to cataract formation, especially with repeated exposure. Patients with eye disease need monitoring if prolonged therapy is anticipated. Ophthalmic formulations can be particularly important in this context.
6.5 Osteoporosis risk
People with low bone density or prior fractures are more vulnerable to skeletal harm from corticosteroids. Preventive steps should be considered before long-term therapy begins. Risk assessment becomes especially important in older adults and postmenopausal women.
6.6 Pregnancy and lactation
During pregnancy and lactation, corticosteroid use requires careful selection of agent, dose, and indication. Some preparations are preferred because they minimize fetal or infant exposure. Treatment should be individualized according to maternal benefit and potential risk.
6.7 Pediatric and geriatric considerations
Children may be more susceptible to growth suppression, while older adults often have higher risks of osteoporosis, diabetes, and skin fragility. Both groups may also metabolize or tolerate corticosteroids differently. These factors influence drug choice, dose, and duration.
7 Drug interactions
Corticosteroids interact with many other medications, sometimes altering steroid concentrations and sometimes changing the effects of the companion drug. Understanding these interactions is important for safe prescribing. Monitoring may be needed when therapy is combined with agents that affect metabolism, electrolytes, or immune response.
7.1 Enzyme inducers and inhibitors
Drugs that induce hepatic enzymes can lower corticosteroid levels, while inhibitors may increase exposure and toxicity. This is especially relevant for agents metabolized by cytochrome systems. Clinicians may need to adjust dosage when such drugs are started or stopped.
7.2 Nonsteroidal anti-inflammatory drugs
Nonsteroidal anti-inflammatory drugs can increase the risk of gastrointestinal irritation and ulcer complications when used with corticosteroids. The combination may be appropriate in some cases, but the added risk should be recognized. Gastroprotective measures are sometimes considered.
7.3 Diuretics and electrolyte effects
When corticosteroids are combined with certain diuretics, potassium loss may be amplified. This can increase the risk of weakness or arrhythmia in susceptible patients. Electrolyte monitoring is useful when both drug classes are used together.
7.4 Vaccines and immunization considerations
Because corticosteroids may suppress immune responses, live vaccines can pose concerns during significant immunosuppressive therapy. Vaccine timing and type should be reviewed before treatment begins. Inactivated vaccines may still be given, though response can be reduced.
7.5 Anticoagulants and antidiabetic drugs
Corticosteroids can alter the effects of anticoagulants and may change the dose requirements of antidiabetic medicines. Blood clotting and glucose control may therefore need closer observation. Medication adjustments are often based on laboratory results and clinical response.
8 Monitoring and management
Effective corticosteroid therapy involves more than choosing the drug itself. Baseline evaluation, ongoing review, and timely dose changes help reduce complications. Long-term treatment especially requires planning for tapering, bone health, and adrenal recovery.
8.1 Baseline assessment
Before initiating corticosteroids, clinicians often assess the underlying condition, current medications, blood pressure, glucose status, bone risk, and infection history. This provides a reference point for later comparisons. Baseline examination also helps identify patients at higher risk for adverse effects.
8.2 Dose selection and tapering
The smallest effective dose is generally preferred, particularly for prolonged treatment. When corticosteroids have been used long enough to suppress adrenal function, tapering is often necessary to prevent withdrawal problems. The taper schedule depends on dose, treatment duration, and clinical response.
8.3 Monitoring for side effects
Follow-up may include checks of blood pressure, weight, blood glucose, mood, and signs of infection. Children may need growth monitoring, and patients on long-term therapy may need bone assessment. Surveillance is tailored to the treatment route and duration.
8.4 Bone protection strategies
For patients at risk of steroid-induced bone loss, preventive strategies may include calcium, vitamin D, exercise, smoking avoidance, and pharmacologic bone protection when indicated. The goal is to reduce fracture risk during chronic therapy. Bone health measures are especially important with repeated systemic courses.
8.5 Stress-dose steroid management
People with adrenal suppression or known adrenal insufficiency may require higher corticosteroid doses during illness, surgery, or major physiologic stress. This temporary increase helps prevent adrenal crisis. Patients often receive instructions for emergency use in advance.
8.6 Adrenal recovery after withdrawal
After prolonged therapy ends, the adrenal glands may need time to resume normal cortisol production. Recovery can be gradual and varies among patients. During this period, symptoms of adrenal insufficiency must be recognized promptly.
9 Special formulations and delivery systems
Advances in formulation have made corticosteroids more adaptable to different diseases and treatment settings. Some products are designed for longer action, stronger local effect, or easier administration. These features can improve adherence and refine therapeutic targeting.
9.1 Extended-release preparations
Extended-release corticosteroids are designed to maintain drug levels over a longer period. They may reduce dosing frequency and provide more sustained symptom control. Such formulations are used in selected conditions where predictable release is beneficial.
9.2 High-potency topical agents
High-potency topical corticosteroids are reserved for severe or resistant skin disorders and for areas where strong local suppression is needed. Their use is limited by the risk of skin thinning and systemic absorption. Treatment duration is usually carefully controlled.
9.3 Nebulized corticosteroids
Nebulized corticosteroids deliver medication as an aerosol for inhalation, often in patients who cannot use standard inhalers effectively. This route can be useful in certain respiratory settings. Proper nebulizer technique helps ensure adequate deposition in the airways.
9.4 Depot injections
Depot injections release corticosteroids slowly over time after a single administration. They can provide prolonged local or systemic effect and are sometimes used when adherence or convenience is a concern. Because the drug cannot be easily removed once injected, caution is important.
10 History and development
The development of corticosteroids transformed modern medicine by providing potent tools for treating inflammation and hormone deficiency. Their history includes discoveries in endocrinology, progress in chemical synthesis, and evolving understanding of long-term safety. These developments shaped contemporary prescribing practices.
10.1 Discovery of adrenal steroids
Research into adrenal gland function identified hormones essential for survival and salt-water balance. Early physiological studies showed that adrenal extracts could treat certain deficiency states. These findings laid the groundwork for hormone isolation and drug development.
10.2 Therapeutic adoption
Once corticosteroids became available for clinical use, they were rapidly adopted for inflammatory and autoimmune conditions. Their dramatic effects in some diseases made them a major therapeutic advance. At the same time, experience with adverse effects led to more cautious dosing.
10.3 Advances in synthetic corticosteroids
Chemical modification produced agents with improved potency, different durations of action, and varied mineralocorticoid effects. These innovations expanded treatment options for specific diseases and routes of administration. Synthetic design also enabled formulations better suited to inhaled, topical, and depot use.
10.4 Modern clinical guidelines
Current practice emphasizes using corticosteroids selectively, at the lowest effective dose, and for the shortest practical duration. Guidelines often recommend route-specific therapy and monitoring for complications. This approach reflects the balance between strong therapeutic benefit and substantial potential harm.